A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro

被引:244
作者
Hugger, ED
Novak, BL
Burton, PS
Audus, KL
Borchardt, RT
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[2] Pharmacia, Drug Absorpt & Transport Grp, Kalamazoo, MI 49007 USA
关键词
P-glycoprotein; Caco-2; cells; MDR1-MDCK cells; polyethoxylated excipients; membrane fluidity;
D O I
10.1002/jps.10176
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
P-glycoprotein (P-gp), a multidrug resistance (MDR) protein encoded by the MDR1 gene in humans, is responsible for the efflux of structurally diverse drugs. Previous studies in our laboratory have shown that excipients such as poly(ethylene)glycol (PEG)300, Cremophor EL, and Tween 80 inhibit P-gp activity in Caco-2 cell monolayers. The objective of this study was to determine the effects of these excipients in an MDR1-transfected Madin Darby Canine Kidney (MDR1-MDCK) cell line and to compare the results with those obtained from Caco-2 cells. The results presented herein show that PEG-300 (20%, v/v) causes almost complete inhibition of P-gp activity in both Caco-2 and MDR1-MDCK cell monolayers, whereas Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) only partially inhibit P-gp activity in Caco-2 cells. Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) were inactive as P-gp inhibitors in MDR1-MDCK cell monolayers. This inability of Tween 80 and Cremphor EL to inhibit P-gp activity in MDR1-MDCK cells may be related to differences in the interactions of the surfactants with these different cell membranes. PEG-induced changes in P-gp activity are probably related to changes in the fluidity of the polar head group regions of cell membranes. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:1991 / 2002
页数:12
相关论文
共 42 条
[1]
Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]
P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels [J].
Anderle, P ;
Niederer, E ;
Rubas, W ;
Hilgendorf, C ;
Spahn-Langguth, H ;
Wunderli-Allenspach, H ;
Merkle, HP ;
Langguth, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (06) :757-762
[3]
Caco-2 monolayers in experimental and theoretical predictions of drug transport [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 22 (1-2) :67-84
[4]
EVIDENCE FOR 21-AMINOSTEROID ASSOCIATION WITH THE HYDROPHOBIC DOMAINS OF BRAIN MICROVESSEL ENDOTHELIAL-CELLS [J].
AUDUS, KL ;
GUILLOT, FL ;
BRAUGHLER, JM .
FREE RADICAL BIOLOGY AND MEDICINE, 1991, 11 (04) :361-371
[5]
Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice [J].
Badary, OA ;
Al-Shabanah, OA ;
Al-Gharably, NM ;
Elmazar, MMA .
ANTI-CANCER DRUGS, 1998, 9 (09) :809-815
[6]
Cell cultures as tools in biopharmacy [J].
Braun, A ;
Hämmerle, S ;
Suda, K ;
Rothen-Rutishauser, B ;
Günthert, M ;
Krämer, SD ;
Wunderli-Allenspach, H .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 :S51-S60
[7]
BRYAN AJ, 1990, INT J PHARM, V7, P145
[8]
THE MADIN DARBY CANINE KIDNEY (MDCK) EPITHELIAL-CELL MONOLAYER AS A MODEL CELLULAR-TRANSPORT BARRIER [J].
CHO, MJ ;
THOMPSON, DP ;
CRAMER, CT ;
VIDMAR, TJ ;
SCIESZKA, JF .
PHARMACEUTICAL RESEARCH, 1989, 6 (01) :71-77
[9]
Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) [J].
Dintaman, JM ;
Silverman, JA .
PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1550-1556
[10]
DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2